Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Rani Therapeutics Holdings (RANI – Research Report), with a price target of $21.00.
Edward Nash provided a Buy rating for Rani Therapeutics Holdings based on a multitude of positive indicators from their recent clinical studies. The data from the Phase I single ascending dose (SAD) study of RT-111, which is an ustekinumab biosimilar, revealed promising pharmacokinetic results when delivered using the RaniPill system. High bioavailability and a rapid time to maximum concentration were among the key outcomes, showcasing the potential efficacy of the drug. Additionally, the presence of anti-drug antibodies was not significantly different from the control group, indicating a favorable safety profile that is comparable to existing treatment methods.
The proposed dosing regimen for RT-111, as announced by Rani Therapeutics, also supports the optimistic outlook. The regimen suggests a feasible and patient-friendly maintenance therapy for plaque psoriasis, involving a 30-day loading phase followed by only three pills per month. This reduced frequency could enhance patient compliance and overall treatment experience. Furthermore, the safety results from the study indicated a comparable adverse event rate between the RaniPill groups and the subcutaneous injection group. The few side effects reported did not seem to correlate directly with the drug’s mechanism, which could point to a generally well-tolerated treatment. These factors collectively contribute to the Buy rating and reflect the potential for RT-111 to become a key player in the treatment of plaque psoriasis.
Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Travere Therapeutics, and Pliant Therapeutics. According to TipRanks, Nash has an average return of -1.2% and a 36.00% success rate on recommended stocks.
In another report released on February 6, Wedbush also reiterated a Buy rating on the stock with a $8.00 price target.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Rani Therapeutics Holdings (RANI) Company Description:
Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. It has developed the RaniPill capsule, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
Read More on RANI:
- Rani Therapeutics Reports Positive Phase 1 Trial Outcomes
- Rani Therapeutics Shares Exciting Clinical Trial Results
- Rani Therapeutics announces topline results from Phase 1 study of RT-111
- Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
- Rani Therapeutics announces preliminary pharmacodynamic data on GLP-1
